2016 American Society of Hematology Annual Meeting*

December 3-6, 2016; San Diego, California
John M. Burke, MD, and Jeff P. Sharman, MD, review data from key lymphoma/CLL presentations at the 2016 American Society of Hematology Annual Meeting.
John M. Burke, MD
Jeff P. Sharman, MD

Lymphomas/CLL

At a median follow-up of 3.5 years, rituximab plus lenalidomide demonstrated durable CR/CRu and prolonged PFS vs rituximab alone in previously untreated in follicular lymphoma.

Released: December 9, 2016

Fixed-dose pembrolizumab achieved an ORR of 69% in heavily pretreated patients with R/R cHL with most responses ongoing for at least 6 months.

Released: December 12, 2016

Ibrutinib demonstrated an ORR of 48% across patients with 3 different subtypes of relapsed/refractory marginal zone lymphoma.

Released: December 12, 2016

Maintenance rituximab after ASCT prolongs EFS, PFS, and OS for younger patients with mantle cell lymphoma vs observation only.

Released: December 6, 2016

Rituximab biosimilar GP2013 plus CVP demonstrated equivalent ORR and comparable safety profile vs rituximab plus CVP as initial therapy for advanced follicular lymphoma.

Released: December 12, 2016

Brentuximab vedotin provided durable objective response and significantly improved CR rates and PFS in patients with CD30+ CTCL.

Released: December 6, 2016

In this study, median PFS with ibrutinib was similar in the clinical trial and real-world settings, although more patients discontinued for treatment-related adverse events in the real-world setting.

Released: December 5, 2016

Median PFS is improved with FCR vs BR in fit younger patients with CLL, although BR remains an option for fit elderly patients with a lower risk of second primary malignancies.

Released: December 9, 2016

Phase III study showed similar EFS and OS with both regimens and increased rate of adverse events with DA-EPOCH-R in DLBCL.

Released: December 7, 2016

Lenalidomide maintenance therapy in elderly patients with DLBCL significantly improved PFS compared with placebo.

Released: December 6, 2016

Obinutuzumab-based therapy reduced the risk of progression or death by 34% compared with rituximab-based therapy in patients with untreated follicular lymphoma.

Released: December 9, 2016

Venetoclax associated with high response rates and durable responses in patients with CLL who progressed on ibrutinib, idelalisib, or both.

Released: December 8, 2016

In this expert analysis, John M. Burke, MD, and Jeff P. Sharman, MD, review key data from the most clinically relevant studies on the management of lymphomas and CLL presented at the Hematology 2016 annual meeting.

John M. Burke, MD Jeff P. Sharman, MD Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: February 8, 2017 Expired: No longer available for credit

Interim analysis reported significantly higher ORR and markedly greater CR with KTE-C19 vs historical rates in chemorefractory patients with DLBCL.

Released: December 9, 2016

In this downloadable slideset, John M. Burke, MD, and Jeff P. Sharman, MD, highlight key data presented at Hematology 2016.

Released: January 5, 2017
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

This activity is supported by educational grants from
Amgen
Celgene Corporation
Incyte
Merck & Co., Inc.
Seattle Genetics

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue